Innovation in Genetic Medicines

We develop precision nucleic acid therapies addressing key clinical unmet needs through strategic development partnerships.

Pipeline/Partnership
Oncology
COVID-19 DNA Vaccines
Age-related Diseases
Program
Partner
Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3
Internal
Undisclosed
Undisclosed
Vaccines
8 Undisclosed programs
Covigenix - VAX-001 Spike protein
Covigenix - VAX-002 Multiple epitopes
OSX-002: Immuno-oncology gene therapy
OncoSenX
OSX-001: p53-targeted suicide gene therapy
OncoSenX
3 undisclosed programs
Senolytic
Undisclosed
OISIN Biotechnologies
Metastasis
Aegis Life
Aegis Life
Genetic Diseases
Multiple genetic disease indications
BioMarin
Neurological Disorders
Multiple neurological indications
Eli Lilly
Entos Pharmaceuticals

33 St James's Square
London, UK, SW1Y 4JS

Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Suite 1100, 3040 Science Park Road
San Diego, CA 92121

General Contact
Tel: 1-800-727-0884
Email: info@entospharma.com

Investor Contact
Email: info@entospharma.com

Media Contact
Email: media@entospharma.com
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.